Start here: what hypertension is
Hypertension is persistently elevated arterial pressure over time, usually tracked by systolic and diastolic measurements from repeated readings. It is common, often silent, and clinically important because sustained pressure elevates long-term risk for stroke, coronary disease, kidney injury, and heart failure [1].
A practical way to think about it is a control problem with two layers: the biologic signal (vascular tone, kidney salt handling, sympathetic output, hormones, inflammation) and the treatment problem (adherence, monitoring cadence, comorbidity priorities). The same office pressure can arise from different mechanisms, so identical numbers can require different treatment strategies [2] [3] [4].
Pillar 1: measurements
Office blood pressure remains the entry test. A diagnosis still starts with repeated measurements because single snapshots are noisy and affected by context [5] [6]. The same is true for risk assessment: transient spikes do not equal sustained burden.
Ambulatory blood-pressure monitoring (ABPM) is the stronger way to capture 24-hour load, nighttime dipping, and morning surge phenotypes, which are often missed by isolated office visits [1]. Home BP adds ecological validity for titration in real life [7].
Target-organ and biochemical work-up matters when readings are high-but-atypical: hypokalemia work-up for mineralocorticoid excess, repeat phenotyping for resistant disease, and secondary-cause testing when onset, severity, or response pattern is unusual [8] [9] [10].
Mechanistic panels are layered rather than replacing BP itself: sodium handling, inflammatory burden, and sleep pattern can refine mechanism when management stalls [6] [11] [12].
Pillar 2: medicines
The treatment anchor is mechanism-aware combination therapy, not one magic class:
- Diuretics help reduce volume load, especially when salt-sensitive physiology is likely [6].
- RAAS-directed options are central for many patients and are especially relevant when kidney and vascular risk are intertwined [13] [8].
- Calcium-channel agents and beta-blocker choices still matter, with individualized selection shaped by comorbidity and heart-rate or ischemia context [14].
- Mineralocorticoid-pathway interventions including newer targeted approaches are increasingly relevant in resistant forms [9] [15].
Newer practice emphasizes adherence systems and behavioral support: if dose escalation fails silently, behavior and measurement cadence often explain outcomes as much as drug choice [5] [16].
Pillar 3: progress
The frontier is less about discovering a stronger single drug and more about integrating better feedback:
- Digital therapeutics and connected workflows improve sustained adherence and data density for outpatient titration [16] [7].
- Salt, sleep, and lifestyle phenotyping increasingly influence both frontline choices and trial inclusion when BP is hard to control [12] [17].
- Device and procedure-based adjuncts are reserved for selected resistant phenotypes and are used after pharmacologic optimization [18].
- Risk framing is shifting from static diagnosis to trajectory reduction (day-night burden, variability, and target-organ trend interpretation) [10] [5].
A simple model: Windkessel-style blood-pressure dynamics
A practical simulatable abstraction is the two-element Windkessel form, which represents arterial load with one compliance state and one resistance term [19]. Let $P(t)$ be arterial pressure, $C$ arterial compliance, $R$ effective resistance, and $Q_{in}(t)$ cardiac inflow. Then:
\[ C\frac{dP}{dt}=Q_{in}(t)-\frac{P(t)}{R} \]
Salt intake and medication can be represented as slow modulations of the model's inputs — parameters that drift between beats rather than within one:
\[ Q_{in}(t)=Q_0\left[1+u_{salt}(t)-u_{med}(t)\right]. \]
For numerical integration with time step $\Delta t$ (seconds), the update is:
\[ P_{t+\Delta t}=P_t+\Delta t\,\frac{Q_{in}(t)-P_t/R}{C}. \]
The timescale matters, and it is short. The model's time constant is $RC$, which for the systemic arterial circulation is on the order of one to two seconds — the diastolic pressure decay between one heartbeat and the next. So what this model explains is the within-beat pressure waveform: how stroke volume, resistance and arterial compliance set systolic and diastolic pressure and therefore the pulse pressure between them, which is exactly what the figure below computes [19].
It does not explain the days-to-weeks fall in pressure seen after starting or switching an antihypertensive. Nothing in a one-to-two-second time constant can produce a multi-week trajectory. That slower response is driven by renal sodium and volume handling and by structural vascular remodeling, which is why diuretics and RAAS-directed agents act on the timescale they do and why salt intake matters over weeks rather than beats [6] [15] [7]. Read the Windkessel as a compliance model, and read the therapeutic trajectory as a volume-and-remodeling story.
Dig deeper in lmmol
Related reviews in this series, all of which intersect blood pressure:
- Chronic kidney disease — the organ that sets long-run blood pressure, and the review covering RAAS blockade as kidney protection.
- Diabetes and the HbA1c biomarker and Obesity — the two conditions most often managed alongside hypertension.
The drug targets and pathway nodes named above:
- Angiotensin-converting enzyme (ACE) — the target of the ACE inhibitors.
- Renin — the enzyme that initiates the cascade.
- Angiotensin II type-1 receptor — the target of the ARBs.
- Endothelial nitric oxide synthase — the vasodilator pathway on the other side of the balance.
And two representative compounds:
- Hydrochlorothiazide — the thiazide diuretic, acting on renal sodium handling.
- Captopril — the first orally active ACE inhibitor.
For entities without a linked static page here, use the graph index, all diseases, or all proteins rather than guessing an entity URL.
Implementation & visualization hooks
lmvideo / diagramkit: render a flow-style system diagram with compliance, resistance, inflow/outflow, and feedback from measurements to medication intensity.